Viruses TRIZ Cases

Astrovirus coat proteins inhibit specific complement pathways, reducing tissue damage while preserving host defense against infection.

Engineered activation-induced cytidine deaminase mutants drive targeted genetic mutations in mammalian cells.

Transplanting human hepatocytes into Fah-deficient FRG mice overcomes poor viability in tissue culture, enabling reliable drug metabolism studies.

A single GATA6 expression pulse breaks symmetry in hiPS cells, enabling rapid co-differentiation of three germ layers into stable organ-like structures.

Recombinant metapneumovirus vectors express multiple viral antigens to overcome safety and efficacy limits of single-strain respiratory vaccines.

Engineered chimeric antigen receptors with specific antigen recognition domains target hematologic malignancies.

Genome-edited immune cells express chimeric antigen receptors targeting CD19, CD70, or BCMA antigens for immuno-oncology applications.

Engineered allogeneic T cells express non-endogenous immunosuppressive polypeptides to enhance persistence in host organisms.

Adding Tbx3 to reprogramming factors resolves low efficiency and poor germ-line competency in somatic cell induction.

Reducing miRNA-let-7a activity in CHO cell cultures extends the productive growth phase and increases specific productivity by at least 25%.

Myostatin-binding peptides inhibit myostatin activity to increase lean muscle mass and treat metabolic disorders.

Combining multiple isolated H3N8 strains with distinct HA antigenic properties overcomes single-strain protection limits against divergent influenza variants.

Optimized CAR linker domains enable precise antigen recognition, resolving solid tumor access barriers.

Plant-produced influenza virus-like particles bypass egg-based limitations by enabling rapid, scalable production of safe and effective vaccine candidates.

Chimeric antigen receptor with optimized heavy and light chain complementarity-determining regions binds GD2-positive tumor cells.

Retroviral particles transduce resting lymphocytes without prior activation, reducing processing time and treatment complexity.

Characterized avian astrovirus isolate enables precise molecular detection and targeted vaccination to prevent runting syndromes.

An integrase-deficient viral vector sustains therapeutic gene levels via heterologous episomal origins, avoiding unpredictable chromosomal integration.

Synthetic retrotransposon genes use human-associated codons to resolve low expression levels and inefficient transposition in gene therapy.

A chimeric antigen receptor targeting human NKG2DL enhances immune cell cytotoxicity against tumor cells.

Identifying incompletely reprogrammed cells via non-CpG hypomethylated regions to resolve variability against profiling complexity.

Infecting ependymal cells with rAAV2 vectors enables widespread protein distribution across brain regions, bypassing blood-brain barrier obstruction.

Composite genetic marker panels enable precise identification of human regulatory T cells through specific ligand binding and antibody detection methods.

Segmented RNA interference therapy targets specific genetic vulnerabilities in chemotherapy-resistant leukemia while sparing normal cells.

A gene expression cassette uses a downstream enhancer to boost protein production levels across various cell types.

CRISPR knockout of MHC Class I eliminates graft-versus-host disease risk, enabling off-the-shelf allogeneic T cell therapies.

Chimeric antigen receptors targeting BCMA enable specific cytotoxic activity against B cell malignancies while sparing humoral immunity.

A dual control system regulates target protein levels using antibiotic-responsive transcription and degradation mechanisms.

A cell-deforming constriction introduces exogenous antigens and adjuvants into T cells for immune modulation.

A bone-targeted alkaline phosphatase fusion protein directs enzyme activity to skeletal tissue via electrostatic peptide interactions.

Uses non-integrating vectors to deliver microRNAs and transcription factors, boosting reprogramming efficiency while preventing genome disruptions.

NK-92 cells engineered with PD-1 CARs eliminate graft-versus-host reactions and enable large-scale production.

Dual costimulatory CAR domains resolve the trade-off between tumor targeting and T cell persistence, enabling sustained anti-tumor immunity.

Blue-light-mediated LINTAD systems control CAR-T cell activation at tumor sites, reducing off-tumor toxicity and cytokine storms.

Fully human monoclonal antibodies bind the respiratory syncytial virus fusion protein to neutralize infection and prevent cell-to-cell spread.

A limited self-replicating mRNA system uses mutated alphavirus replicase to sustain target protein production.

Isozyme-selective SRD5AIII inhibitors suppress local DHT synthesis to overcome incomplete remission in androgen-stimulated prostate cancer.

Synthetic promoters with inflammation response elements restrict chimeric antigen receptor activity to tumor sites, reducing toxicity to normal tissues.

Distinct CDR3 sequences in anti-Claudin 18.2 antibodies prevent cross-reactivity with Claudin 18.1, resolving off-target binding issues.

Removing SOCS, SHP, and PIAS regulators breaks self-tolerance to induce potent antigen-specific immune responses against cancer.

Compartmentalizing target organs isolates nucleic acid delivery from systemic circulation, reducing toxicity while ensuring sustained gene expression.

Retroviral vectors deliver de-differentiation factors to transform human fibroblasts into induced pluripotent stem cells.

Coexpressing interleukin-7 and CCL19 in CAR-T cells counters immunosuppressive tumor microenvironments.

Messenger UNA molecules boost translation efficiency through unlocked nucleomonomers, extending half-life against RNase degradation.

Surfactant-nickel complexes prevent tissue factor denaturation, resolving stability versus measurement precision trade-offs in clotting reagents.

Cleaving the TRAC locus in allogeneic T cells prevents graft-versus-host disease while enabling targeted antileukemic activity.